ECM
CLVS

Endurant Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Endurant Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-30,500
Closed -$1.39M – 88
2018
Q2 		$1.39M Sell
30,500
-2,600
-8% -$126K 0.6% 41
2018
Q1 		$1.75M Sell
33,100
-34,550
-51% -$2.02M 0.65% 39
2017
Q4 		$4.6M Buy
67,650
+10,900
+19% +$762K 1.41% 33
2017
Q3 		$4.68M Buy
56,750
+25,100
+79% +$1.99M 1.42% 25
2017
Q2 		$2.96M Sell
31,650
-200
-0.6% -$12.2K 0.84% 35
2017
Q1 		$2.03M Buy
31,850
+13,450
+73% +$818K 0.65% 44
2016
Q4 		$817K Buy
18,400
+10,100
+122% +$355K 0.34% 56
2016
Q3 		$299K Buy
+8,300
New +$178K 0.11% 91

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Endurant Capital Management's CLVS Position: Q3 2018 in Review

Endurant Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 30,500 shares — an estimated $1.39M sold.

Endurant Capital Management first reported a position in CLVS in Q3 2016 and held it in 8 quarters. The position peaked at $4.68M in Q3 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Endurant Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Endurant Capital Management sold 30,500 Clovis Oncology, Inc. shares in Q3 2018, an estimated $1.39M.
  • Endurant Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 8 quarters.
  • Endurant Capital Management's Clovis Oncology, Inc. position peaked at $4.68M in Q3 2017.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.